ArticleResearch square2026

A first-in-class precision antibody conjugate targeting EGFR, mTOR, and PI3K to treat head and neck cancers.

Xiaoyi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.